Tenaya Therapeutics, Inc. TNYA
Set alert
At close
Pre-market · Nov 3, 4:00 AM ET
- YTD
- -49.30%
- 1 year
- -74.93%
- Open
- 0.3716
- Prev close
- 0.3674
- Mkt cap
- 82.28M
- Vol
- 2.29M
- Avg vol
- 2.78M
- EPS
- -0.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.361
- High
- 0.3811
- Forward P/E
- -1.28
- Beta
- 2.35
- Short ratio
- 2.31
- Inst. own
- 73.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.40
- 200-d avg
- 3.26
- 1y target
- 18.50
3M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
Key statistics
- Market cap
- 125.96M
- Enterprise value
- 67.37M
- Trailing P/E
- 0.00
- Forward P/E
- -1.28
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.12
- EPS (TTM)
- -1.44
- Beta
- 2.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -56.52M
- Total cash
- 79.47M
- Total debt
- 14.54M
- Return on equity
- -84.49%
- Shares outstanding
- 79.22M
- Short % of float
- 25.39%
- 50-day average
- 2.40
- 200-day average
- 3.26
Analyst view
Consensus: strong buy
- Target (low)
- 6.00
- Target (mean)
- 18.50
- Target (high)
- 40.00
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.315.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.37 | -0.30 | +0.07 | +18.92% |
| Aug 8, 2024 | Jun 1, 2024 | -0.40 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.40 | -0.34 | +0.06 | +15.00% |
| May 14, 2024 | Mar 1, 2024 | -0.43 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.43 | -0.40 | +0.03 | +6.98% |
| Mar 18, 2024 | Dec 1, 2023 | -0.45 | -0.40 | +0.05 | +11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | Chardan Capital | main | Buy | Buy |
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 7, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 18, 2024 | Canaccord Genuity | main | Buy | Buy |
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tenayatherapeutics.com
News
Your note
Sign in to keep a note on TNYA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI FARAZ | Chief Executive Officer | Sale | Aug 15, 2024 | 188,331 |
| COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 0 |
| GOEDDEL DAVID V | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 0 |
| HOEY TIMOTHY | Officer | Sale | Mar 4, 2024 | 245,346 |
| PATTERSON LEONE D. CPA | Chief Financial Officer | Stock Award(Grant) | Feb 22, 2024 | 95,755 |
| SAITO CHIHIRO | Officer | Sale | Nov 17, 2024 | 60,983 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Column Group LLC | 11.87% | 9,400,290 | 14.95M | Sep 29, 2024 |
| RA Capital Management, L.P. | 8.81% | 6,982,587 | 11.10M | Sep 29, 2024 |
| Casdin Capital, LLC | 8.50% | 6,732,971 | 10.71M | Sep 29, 2024 |
| Blackrock Inc. | 5.18% | 4,106,305 | 6.53M | Sep 29, 2024 |
| Vanguard Group Inc | 4.06% | 3,213,167 | 5.11M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 3.82% | 3,028,435 | 4.82M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 2.65% | 2,099,086 | 3.34M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.61% | 2,064,246 | 3.28M | Sep 29, 2024 |
| Fidelity Select Portfolios - Biotechnology | 2.20% | 1,746,113 | 2.78M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 1.80% | 1,428,719 | 2.27M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.87% | 691,525 | 1.10M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.72% | 567,023 | 901.57K | Aug 30, 2024 |